Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
11521
-
11522
-
11523
-
11524
-
11525
RLIPC elevates ST segment prior to induction of cardiac ischemia in rat model of arrhythmia.
Published 2016“…LVSP, left ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure; ±dP/dtmax, maximum rate of increase/decrease in left ventricular pressure. Data are the mean±SEM (<i>n = 6–7</i> in each group). …”
-
11526
-
11527
Decreased branching, partial right isomerization and epithelial proximalization in CKO lungs.
Published 2008“…<p>(a–d) β-gal staining of <i>Dermo1<sup>Cre/+</sup>/Rosa26R</i> WT lungs at E11.5 and E13.5 reports Cre recombination activity in the mesenchyme of the embryonic lung. …”
-
11528
-
11529
-
11530
-
11531
-
11532
Effects of a clinical medication review focused on personal goals, quality of life, and health problems in older persons with polypharmacy: A randomised controlled trial (DREAMeR-s...
Published 2019“…Over 6 months, in the intervention group, HR-QoL measured with EQ-VAS increased by 3.4 points (95% confidence interval [CI] 0.94 to 5.8; <i>p</i> = 0.006), and the number of health problems with impact on daily life decreased by 12% (difference at 6 months −0.34; 95% CI −0.62 to −0.044; <i>p</i> = 0.024) as compared with the control group. …”
-
11533
-
11534
The estrogen receptor-α agonist PPT decreases cardiac myofilament activation.
Published 2013“…<p>Myocardium was treated with the estrogen receptor-α agonist PPT (100 nM) for 1 (A) (N = 9), 2.5 (B) (N = 9), or 5 min (C) (N = 22). …”
-
11535
-
11536
-
11537
-
11538
-
11539
Expression of <i>Foxf1a</i> and <i>Foxf2</i> in <i>shh<sup>−/−</sup></i> and <i>Tbx5<sup>+/−</sup></i> mutants embryos at E9.5.
Published 2014“…<i>Tbx5</i> heterozygotes expressed <i>Foxf1a</i> at decreased levels specifically in the posterior SHF tissues (C, D), whereas <i>Foxf2</i> expression patterns were unchanged (G, H). …”
-
11540